Zimmer Biomet beats profit estimates on strong demand for medical devices
Aug 7 (Reuters) -Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
Peer Stryker Corp SYK.N last month raised its annual profit outlook betting on robust demand for its hip and knee implants.
Zimmer, however, cut its annual revenue growth forecast anticipating a higher foreign currency impact. Zimmer now sees revenue growth of 4% to 5% from a year earlier, compared to 4.5% to 5.5% growth forecast previously.
Combined sales at Zimmer's hips and knees units came in at $1.31 billion, shy of analysts' estimate of $1.32 billion, according to LSEG data.
The company also saw strong sales at its unit that sells sports medicine and trauma care products. Sales at the unit rose 6.1% year-over-year to $469.5 million, topping estimates of $465.4 million.
Separately, Zimmer said on Tuesday it would acquire OrthoGrid Systems, a privately held medtech firm to gain access to its artificial intelligence-driven surgical guidance systems for total hip replacement.
The hip and knee implant maker reiterated its full-year 2024 profit expectations in the range of $8.00 to $8.15 per share. Analysts were expecting annual profit of $8.09 per share.
Zimmer's second-quarter revenue rose nearly 4% to $1.94 billion, in-line with analysts' average estimates.
On an adjusted basis, the company posted a profit of $2.01 per share in the quarter ended June 30, topping estimates of $1.99 per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
